Targeted Treatment against Lipoprotein(a): The Coming Breakthrough in Lipid Lowering Therapy

This review frames Lp(a)-lowering as “the coming breakthrough” in lipid therapy — capturing the optimism of a field that has long had a major risk factor with no treatment.

The authors recap the case for Lp(a) as an independent, genetically fixed cardiovascular risk factor, then turn to the new RNA-based drugs — pelacarsen, olpasiran, SLN360 — that can cut Lp(a) by up to 98%, a magnitude no prior therapy approached. The premise is that, for the first time, the Lp(a) hypothesis can actually be tested in outcome trials.

The practical takeaway is anticipatory: clinicians should be ready to integrate Lp(a)-lowering therapy once the outcome trials read out. The resistance comes from incumbents in the statin/PCSK9 market and guideline caution.

We rate the evidence moderate: a 76-reference review with strong mechanistic rationale, though one author (Banach) discloses industry ties, transparently noted. Its clinical significance is high in prospect — a treatment for elevated Lp(a) would matter for millions — but contingent on the trials that hadn’t yet reported. One of several Lp(a)-therapy reviews in this library converging on the same hopeful, not-yet-proven horizon.